Hinge Health (NYSE:HNGE) CFO James Budge Sells 781 Shares of Stock

Hinge Health Inc. (NYSE:HNGE) CFO James Budge sold 781 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $55.34, for a total transaction of $43,220.54. Following the completion of the transaction, the chief financial officer directly owned 451,293 shares of the company’s stock, valued at approximately $24,974,554.62. This trade represents a 0.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Budge also recently made the following trade(s):

• On Monday, May 11th, James Budge sold 5,906 shares of Hinge Health stock. The shares were sold at an average price of $54.82, for a total transaction of $323,766.92.
• On Monday, March 23rd, James Budge sold 11,006 shares of Hinge Health stock. The stock was sold at an average price of $42.26, for a total transaction of $465,113.56.

Hinge Health Price Performance

Hinge Health stock opened at $55.11 on Friday. The company has a market cap of $4.26 billion and a price-to-earnings ratio of -4.47. The firm has a 50-day moving average of $44.84 and a 200-day moving average of $44.35. Hinge Health Inc. has a one year low of $30.08 and a one year high of $62.18.

Hinge Health (NYSE:HNGE) last released its earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.33. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The business had revenue of $182.31 million for the quarter. During the same period in the prior year, the firm posted $1.30 EPS. Hinge Health’s revenue was up 47.2% compared to the same quarter last year. As a group, sell-side analysts expect that Hinge Health Inc. will post 1.21 earnings per share for the current year.

Institutional Investors Weigh In On Hinge Health

Several hedge funds have recently bought and sold shares of HNGE. Vanguard Group Inc. lifted its holdings in Hinge Health by 22.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,237,839 shares of the company’s stock worth $60,753,000 after purchasing an additional 228,234 shares during the last quarter. UBS Group AG grew its holdings in Hinge Health by 168.8% in the 4th quarter. UBS Group AG now owns 356,701 shares of the company’s stock valued at $16,569,000 after buying an additional 223,980 shares in the last quarter. Tudor Investment Corp ET AL grew its holdings in Hinge Health by 25.9% in the 3rd quarter. Tudor Investment Corp ET AL now owns 376,266 shares of the company’s stock valued at $18,467,000 after buying an additional 77,464 shares in the last quarter. First Eagle Investment Management LLC bought a new position in Hinge Health during the 3rd quarter worth $4,074,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Hinge Health by 755.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company’s stock worth $1,271,000 after buying an additional 24,155 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Evercore reissued an “outperform” rating and issued a $45.00 price objective on shares of Hinge Health in a report on Wednesday, April 8th. KeyCorp set a $55.00 price target on shares of Hinge Health in a research note on Wednesday, February 11th. Stifel Nicolaus lifted their price objective on shares of Hinge Health from $59.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Freedom Capital upgraded shares of Hinge Health to a “strong-buy” rating in a research note on Thursday, January 22nd. Finally, Needham & Company LLC upped their target price on shares of Hinge Health from $59.00 to $63.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.40.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.